CDT Equity Inc.
CDTHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeCDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. Valued at $2.4M, CDT is a micro-cap name in its sector. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Market Cap
$2.4M
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-87.43
EPS (Fwd)
—
ROE
-71.0%
ROA
-25.2%
Cash
$97,000
Total Debt
$852,000
Free CF
$17.9M
52W Change
-99.9%
Annual Financials
Cash vs Debt
Where CDT stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CDT finished 97.72% below its 150-day moving average ($15.32) and 98.91% below its 200-day moving average ($32.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDT overbought or oversold?
At the July 15, 2026 close, CDT's RSI(14) was 0.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CDT has $97K in cash with $852K in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $17.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -71.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
CDT Equity Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CDT Equity Inc.'s trajectory.